- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1025504-45-3] Valbenazine
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-16771 |
| Brand: | MCE |
| CAS: | 1025504-45-3 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 418.57 |
| Molecular Formula | C24H38N2O4 |
| SMILES | O=C([C@@H](N)C(C)C)O[C@@H]1C[C@]2([H])C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC(C)C |
1 Publications Citing Use of MCE
Summary
Valbenazine (NBI-98854) is a vesicular monoamine transporter 2 ( VMAT2 ) inhibitor with the K i of 110-190 nM [1] .
In Vitro
Valbenazine exhibits VMAT2 binding affinity in rat striatum and human platelets with Kis of 110 and 150 nM, respectively [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Valbenazine (10 mg/kg; orally) induces ptosis (primarily an adrenergic response) and increases plasma prolactin primarily a dopaminergic response in rats [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02879578 | Neurocrine Biosciences |
Tourette Syndrome
|
July 25, 2016 | Phase 2 |
| NCT01733121 | Neurocrine Biosciences |
Tardive Dyskinesia
|
December 2012 | Phase 2 |
| NCT03891862 | Neurocrine Biosciences |
Tardive Dyskinesia (TD)
|
March 18, 2019 | Phase 4 |
| NCT05110157 | Neurocrine Biosciences |
Schizophrenia
|
November 29, 2021 | Phase 3 |
| NCT01267188 | Neurocrine Biosciences |
Tardive Dyskinesia
|
January 2011 | Phase 2 |
| NCT02405091 | Neurocrine Biosciences |
Tardive Dyskinesia
|
March 2015 | Phase 3 |
| NCT02274558 | Neurocrine Biosciences |
Tardive Dyskinesia
|
October 2014 | Phase 3 |
| NCT05206513 | Neurocrine Biosciences |
Dyskinesia|Cerebral Palsy
|
April 15, 2022 | Phase 3 |
| NCT01688037 | Neurocrine Biosciences |
Tardive Dyskinesia
|
September 2012 | Phase 2 |
| NCT03530293 | Neurocrine Biosciences |
Tourette Syndrome
|
April 17, 2018 | Phase 2 |
| NCT02581865 | Neurocrine Biosciences |
Tourette Syndrome
|
November 2015 | Phase 2 |
| NCT01916993 | Neurocrine Biosciences |
Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
|
August 2013 | Phase 1 |
| NCT01910480 | Neurocrine Biosciences |
Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects
|
July 2013 | Phase 1 |
| NCT03732534 | Neurocrine Biosciences |
Tourette Syndrome
|
October 17, 2018 | Phase 2 |
| NCT04102579 | Neurocrine Biosciences|Huntington Study Group |
Chorea, Huntington
|
November 13, 2019 | Phase 3 |
| NCT03698331 | Neurocrine Biosciences |
Tardive Dyskinesia (TD)
|
September 14, 2018 | Phase 4 |
| NCT01393600 | Neurocrine Biosciences |
Tardive Dyskinesia
|
August 2011 | Phase 2 |
| NCT02256475 | Neurocrine Biosciences |
Tourette Syndrome
|
September 2014 | Phase 1 |
| NCT03444038 | Neurocrine Biosciences |
Tourette Syndrome
|
February 8, 2018 | Phase 2 |
| NCT03325010 | Neurocrine Biosciences |
Tourette Syndrome
|
October 5, 2017 | Phase 2 |
| NCT02679079 | Neurocrine Biosciences |
Tourette Syndrome
|
March 23, 2016 | Phase 2 |
| NCT02736955 | Neurocrine Biosciences |
Tardive Dyskinesia
|
June 13, 2016 | Phase 3 |
| NCT04400331 | Neurocrine Biosciences|Huntington Study Group |
Chorea, Huntington
|
September 18, 2020 | Phase 3 |
| NCT05053321 | Yale University|Neurocrine Biosciences |
Tardive Dyskinesia
|
November 2022 | Phase 1 |
| NCT05207085 | Yale University|Neurocrine Biosciences |
Trichotillomania (Hair-Pulling Disorder)
|
November 15, 2022 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 119.45 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3891 mL | 11.9454 mL | 23.8909 mL |
| 5 mM | 0.4778 mL | 2.3891 mL | 4.7782 mL |
| 10 mM | 0.2389 mL | 1.1945 mL | 2.3891 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.97 mM); Clear solution
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.